Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with microsatellite instable tumors.

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

Researchers used mutational analysis to identify gene mutations that may drive carcinogenesis in colorectal tumors with high ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on genetic mutations.

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that its comprehensive genomic profiling assay Northstar ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

The FDA approved the use of Opdivo with Yervoy in front-line colorectal cancer, while a Manhattan court junked a class action ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) ...